The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
HOME > ORGANIZATION
ORGANIZATION
- JEMA Proposing “Improved Drug” Category with Minimal Application Dossiers
March 10, 2025
- Cough Drug Asverin Tops Supply Shortage Ranking in Japan: P-Cubed Survey
March 6, 2025
- JPMA President Demands Rethink of Social Security Expenditure Cap
February 27, 2025
- People’s Trust in Pharma Industry Down to 83.9% in 2024: JPMA Poll
February 27, 2025
- Japan Pharma Lobbies Likely to Enter Yasukawa/Miyabashira Era toward FY2026 Reform
February 26, 2025
- Policy Veterans’ Group Urges Japan to More than Double Minimum Drug Prices
February 21, 2025
- JPMA to Put Japan’s Social Security Spending Cap Up for Discussion: Exec
February 21, 2025
- Create NDA Category Modeled after FDA’s “505(b)(2)” Pathway: JEMA
February 20, 2025
- Generic Rate Tops 80% in All Prefectures for 1st Time in September: Payer
February 14, 2025
- US Lobbies Send Letters of Protest to Japan Embassy over Off-Year Revision, CEA
February 10, 2025
- Include Single IRB Policy in GCP to Accelerate Trials: EFPIA Official
February 10, 2025
- Role of IP Division Shifting to Partner Hunt and Dealmaking: JPMA Official
February 5, 2025
- Ex-Govt Advisor Calls for Discussions on Elective Scheme for Biologics
January 29, 2025
- JPMA Exec Urges Rethink of Social Security Funding; Comments on Trump’s Policy
January 24, 2025
- Japan Biosimilar Association Ready to Play Its Roles under Govt Roadmap
January 17, 2025
- JGA to Launch Scheme for Requesting Production Ramp-Up in March: President
January 14, 2025
- Drug Price Cuts for 8 Years Straight Is Big Burden: Trade Group Chief
January 9, 2025
- Pharma CEOs Discouraged by Off-Year Revision, but Give Certain Credit to Category-Based Scope
January 9, 2025
- FPMAJ Chair Calls for Sufficient Consensus on Drug Discovery Support Fund
January 7, 2025
- 4-Ministers’ Pact Has Effectively Been Scrapped with 2025 Off-Year Revision Plan: FPMAJ Chair
January 7, 2025
ページ
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…